Latest News

Gross hematuria is a distressing symptom for patients with upper urinary tract urothelial cancers (UTUC). Invasive procedures are usually employed to control hematuria, including surgical resection, endoscopic laser ablation, and percutaneous nephroscopic resection. Stereotactic body radiation therapy (SBRT) is a non-invasive, targeted radiation therapy technique frequently applied in curative and palliative settings. It involves a […]

Ashish Kamat: Hello, and welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat, Professor of Urologic Oncology and Cancer Research at MD Anderson Cancer Center in Houston, Texas. And it is my pleasure to welcome a friend, colleague, and an expert in the field, Dr. Yair Lotan from UT Southwestern Medical Center up […]

Cancer therapy-induced bone loss (CTIBL), occurring especially in hormone-treated breast and prostate cancer patients, is a noteworthy long-term consequence of cancer treatments. Because of its negative impact on the quality life of cancer survivors, it deserves much attention.

Several patient-reported outcome measures (PROMs) are available for the assessment of quality of life (QoL), anxiety and depression for testicular cancer (TCa); however, these PROMs have uncertain validation of their psychometric properties for TCa-only cohorts.

Renal cell carcinoma (RCC) accounts for 2-3% of all tumors being the most frequent solid lesion in the kidney. To determine what genetic alterations and immunohistochemical (IHC) of clear cell renal carcinoma (ccRCC) are associated with prognosis and tumor aggressiveness.

DNA methylation is frequently observed in the development and progression of many human tumors as well as renal cell cancer (RCC). Tumor Associated Calcium Signal Transducer 2 (TACSTD2) participates in cell cycle progression through MAPK signalling pathway activation.

ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [18F]-fluoride (NaF) PET imaging.

Previous cancer-specific mortality (CSM) analyses for different Gleason patterns in Gleason grade group (GGG) 5 cancer were limited by sample size. To test for differences in CSM according to biopsy GG 5 patterns (4 + 5 vs 5 + 4 vs 5 + 5) among patients undergoing radical prostatectomy (RP) or external beam radiation therapy […]

To examine the relationship between influential factors and treatment decisions among men with newly diagnosed prostate cancer (PCa). We identified men in the Michigan Urological Surgery Improvement Collaborative registry diagnosed with localized PCa between 2018-20 who completed Personal Patient Profile-Prostate (P3P).

Patient-derived organoids (PDOs) represent promising preclinical models of various tumor types. In the context of prostate cancer (PCa) however, their establishment has been hampered by poor success-rates, which impedes their broad use for translational research applications.